BI’s Cyltezo to test value of interchangeable label for Humira

Approval of Cyltezo, the first interchangeable version of Humira, is an important milestone for its manufacturer, Boehringer Ingelheim, which has been developing the product for almost a decade, but it is far from clear how much the company will receive in return for its lengthy and complex development program.

The effect of Cyltezo adalimumab-adbm on one of the most durable and lucrative franchises in the history of medicine — and a poster child for arguments that pharmas abuse the social contract by extending exclusivity longer than the law intends — is even less certain. ...